Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes
Status:
Completed
Trial end date:
2018-04-09
Target enrollment:
Participant gender:
Summary
Approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect
hypoglycaemia, a condition referred to as impaired hypoglycaemic awareness (IHA) that causes
a six-fold higher risk of severe, potentially hazardous, hypoglycaemia. IHA is usually the
end-result of a process of habituation to recurrent hypoglycemia that is potentially
reversible. Treatment with glucagon-like peptide (GLP)-1 Receptor Agonists (1RAs) in addition
to insulin therapy may decrease the incidence of hypoglycaemia in patients with type 1
diabetes. This study will test the hypothesis that treatment with the GLP-1RA, exenatide,
added to basal-bolus insulin therapy will improve awareness of hypoglycaemia in patients with
type 1 diabetes and IHA. In a randomized doubleblind placebo-controlled cross-over trial,
patients will be treated for 6 weeks with exenatide (or placebo), after which hypoglycemic
symptoms and counterregulatory hormone responses will be examined during a hyperinsulinemic
hypoglycemic glucose clamp study.